Clinical relative bioavailability of AZD3293, a novel beta-site amyloid precursor protein cleaving enzyme 1 inhibitor: Assessment of tablet formulation versus oral solution and gastrointestinal effect on pharmacokinetics

The requested reference [ccf04e2c3ae4075c5e211982218f8e7e48414788] no longer exists in our database. It has been replaced by the current reference: [1ab91e828b29dd031ca74299f2aafb7584bdef63]

Authors
Category Primary study
JournalNeurotherapeutics
Year 2016
This article has no abstract
Epistemonikos ID: b86802e388f884b4fbaa5bd35215c762905fe46f
First added on: Feb 08, 2025